Format

Send to

Choose Destination
Clin Infect Dis. 2018 May 2;66(10):1566-1572. doi: 10.1093/cid/cix1055.

Randomized Controlled Trial of Daily Text Messages to Support Adherence to Preexposure Prophylaxis in Individuals at Risk for Human Immunodeficiency Virus: The TAPIR Study.

Author information

1
University of California, San Diego.
2
University of Southern California, Keck School of Medicine, Los Angeles.
3
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center; Long Beach, California.
4
Long Beach Department of Health and Human Services, Long Beach, California.
5
University of Colorado, Denver, Foster City, California.
6
Gilead Sciences, Inc, Foster City, California.

Abstract

Background:

Adherence is critical for efficacy of tenofovir disoproxil fumarate/emtricitabine (FTC) as preexposure prophylaxis (PrEP).

Methods:

Between February 2013 and February 2016, 398 men who have sex with men and transgender women were randomized 1:1 to receive individualized texting for adherence building (iTAB) or standard care (SoC) for 48 weeks. The primary endpoint was dried blood spot (DBS) tenofovir diphosphate (TFV-DP) concentrations at both week 12 and the last on-drug visit of >719 fmol/punch (ie, adequate adherence). Secondary outcomes included DBS TFV-DP concentrations of >1246 fmol/punch (ie, near-perfect adherence) and plasma FTC >350 ng/mL (consistent with dosing within the past 24 hours).

Results:

Concentrations >719 fmol/punch of TFV-DP were found in 88.6% of participants at week 12 and 82.5% at week 48. For the primary endpoint, the study arms did not differ (72.0% in iTAB and 69.2% in SoC; P > .05). For the secondary composite endpoint of >1246 fmol/punch the iTAB arm was superior to SoC (33.5% vs 24.8%; P = .06), reaching statistical significance when adjusting for age (odds ratio, 1.56 [95% confidence interval, 1.00-2.42]; P < .05). At week 48, iTAB was superior to SoC for near-perfect adherence (51.0% vs 37.4%; P = .02). At week 12, iTAB was superior to SoC for dosing in past 24 hours by plasma FTC (47.5% vs 33.3%; P = .007), but not at weeks 24, 36, and 48 (all P > .05).

Conclusions:

Automated text messaging is a low-burden tool that improves durability of near-perfect PrEP adherence.

Clinical Trials Registration:

NCT01761643.

PMID:
29228144
DOI:
10.1093/cid/cix1055

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center